top of page
$4.92
chg
-0.14 (-2.77%)
quotes and stock data may be delayed 15 minutes
My Notes
Only BPIQ Pro members can create company notes. Learn more here.
52 wk low
4.85
52 wk hi
13.97
Cash
$141.1M
Burn Rate (Qtr)
$25.5M
Mkt Cap
$265.4m
Avg Volume
1,030,203
*cash/burn updated:
Q4 '21
Drug Pipeline
Click the button to see the updated pipeline
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
Catalyst Date
Loading Catalysts...
search in progress
Pipeline powered by
CARA
Company Profile
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).
Recent Posts
See what the community is saying - click to see full post.
bottom of page